Outcome of Allogeneic Hemopoietic Stem Cell Transplantation in Patients with Lymphoma

Abstract

ematopoietic stem cell transplantation (HSCT) has become the standard of care for many patients with defined congenital or acquired disorders of the hematopoietic system or with chemosensitive, radiosensitive, or immunosensitive malignancies. Non-Hodgkin lymphoma (NHL) is a heterogeneous group of hematologic malignancies, known to be associated with chronic inflammatory diseases such as Sjögren syndrome, celiac disease, and rheumatoid arthritis. Autologous stem cell transplantation (SCT) has frequently been used in these patients because these lymphomas are generally very sensitive to chemotherapy and radiation therapy. The percentage of allogeneic HSCT for lymphoma has markedly increased over recent years due to the introduction of reduced-intensity conditioning allogeneic HSCT.